Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
6,537 people get CELG articles and Market Currents by email alert.
Get email alerts on CELG »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Business Wire (Apr 29, 2013)
-
-
-
-
-
Business Wire (Apr 25, 2013)
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Celgene Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012
-
Celgene Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Celgene's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Celgene Management Discusses Q4 2011 Results - Earnings Call TranscriptThu, Jan 26, 2012 • 1 Comment
-
Celgene Corporation - Shareholder/Analyst CallMon, Dec 12, 2011
-
Celgene Management Discusses Q3 2011 Results - Earnings Call TranscriptThu, Oct 27, 2011
-
Celgene Management Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 28, 2011
-
Celgene's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 28, 2011 • 2 Comments
-
Celgene's CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Jan 27, 2011
-
Celgene CEO Discusses Q3 2010 Results - Earnings Call TranscriptThu, Oct 28, 2010
-
Celgene Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Celgene Q1 2010 Earnings Call TranscriptFri, Apr 30, 2010
-
Celgene Corporation Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010
-
Celgene Corporation Q3 2009 Earnings Call TranscriptThu, Oct 22, 2009
-
Celgene Corporation Q2 2009 Earnings Call TranscriptThu, Jul 23, 2009
-
at MarketWatch.com (Thu, 4:28PM)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 9, 2013)
-
at Fox Business (May 2, 2013)
-
Business Wire (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 20, 2013)
-
at CNBC.com (Apr 19, 2013)
-
at CNBC.com (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 3, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at Fox Business (Apr 1, 2013)
CELG vs. ETF Alternatives
Company Description
Celgene Corporation and its subsidiaries (collectively “we” or “our”) is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
- Monday, May 6, 3:09 PM Celgene (CELG +0.5%) says Apremilast achieves statistical significance for its primary endpoint in the first company-sponsored study of psoriatic arthritis patients who had not previously received oral DMARDs. This is the fourth randomized Phase III study of the treatment to show promising results. Last month, Deutsche Bank called the drug a potential "blockbuster" in a note accompanying an upgrade. 2 Comments [Healthcare]
- Friday, April 26, 8:53 AM Celgene (CELG) says based on a Phase III trial, the Committee for Medicinal Products for Human Use has recommended REVLIMID for approval regarding the treatment of transfusion-dependent anemia due to MDS when other therapies aren't sufficient or prove inadequate. Shares +.85% premarket after falling marginally Thursday following Q1 results. Comment! [Healthcare]
- Thursday, April 25, 8:01 AM More on Celgene (CELG) Q1 earnings: REVLIMD sales +16% Y/Y to $1B, light of consensus of $1.1B. ABRAXANE sales of $123M and VIDAZA of $204M inline. SG&A expenses of $333M, +11.3%. Purchased approximately 4.2M shares at cost of $403M (average price $95.95). FY2013 EPS guidance raised to $5.55-$5.65 from $5.50-$5.60. Shares -0.9% premarket. Conference call at 9 ET. (PR) Comment! [Healthcare, On the Move, Earnings]
- Thursday, April 25, 7:30 AM Celgene (CELG): Q1 EPS of $1.37 beats by $0.01. Revenue of $1.46B (+15% Y/Y) misses by $0.01B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Monday, April 22, 8:02 AM Celgene (CELG) +1.8% premarket as Cantor Fitzgerald reiterates the stock a Buy and raises its price target to $142. Comment! [Healthcare, On the Move]
- Friday, April 5, 8:13 AM Celgene (CELG) gets an upgrade from Deutsche Bank to Buy from Hold. The bank says survey data gathered from 100 dermatologists and rheumatologists suggests Apremilast is a "blockbuster." DB raises its price target from $105 to $143. Shares +1.4% premarket. 2 Comments [Healthcare, On the Move]
- Thursday, April 4, 9:51 AM Cyclacel (CYCC -2.8%) sells four patents to Celgene (CELG +0.8%) for a onetime payment of $5.5M, effectively resolving pending litigation between the two companies. Cyclacel is now free to get back to focusing "on the development of [its] pipeline," CEO Spiro Rombotis says. Comment! [Healthcare]
- Thursday, March 28, 4:24 PM Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 1 Comment [Healthcare]
- Monday, March 11, 9:34 AM The National Comprehensive Cancer Network (NCCN) adds the combination of carfilzomib, which is sold by Onyx Pharmaceuticals (ONXX), lendalidomide (made by Celgene (CELG)) and dexamethasone to its guidelines as an option for treating multiple myeloma patients who are also transplant candidates. The NCCN also adds carfilzomib monotherapy and other agents as a preferred treatment regimen for salvage therapy. The FDA hasn't approved carfilzomib for these uses, so Onyx won't market carfilzomib for them. Comment! [Healthcare]
- Monday, March 4, 9:37 AM Celgene (CELG) -2.2% as hopes fade that the company's Apremilast anti-inflammatory treatment can become a blockbuster. At the weekend, Celgene released disappointing results for Apremilast from a Phase III trial of patients with psoriasis, an autoimmune skin disease. Comment! [Healthcare]
- Sunday, March 3, 9:02 AM Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just 33% of patients had a 75% reduction in psoriasis vs. 41% in the midstage trial. Management had hoped for $1.1B-$1.75B in peak sales for the drug, a figure few on the Street were buying. (PR) 3 Comments [Healthcare]
- Sunday, March 3, 4:02 AM Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an autoimmune skin disease, by 75% in a third of patients in a Phase III trial. However, that's below the 41% rate in a Phase II study, raising doubts about whether Apremilast will meet Celgene's hopes and become a new blockbuster drug. Apremilast would compete with rival medicines from AbbVie (ABBV) and Amgen (AMGN). (PR) Comment! [Healthcare]
- Wednesday, February 20, 8:45 AM Celgene (CELG +1.8%) agrees to buy back $600M in stock from an investment bank as part of its repurchase program. So far this year, the company has bought back $385M in shares and has $1.45B remaining in the scheme. Celgene has repurchased $5.05B of stock over the past four years. 1 Comment [Healthcare, On the Move]
-
- View all 0 replies
-
Capitalist Bull
Leading growth stocks taking a break while the $ES_F shows no signs of fatigue. http://stks.co/qD73 $NFLX $REGN $SPWR $GOOG $CELG $NSM - View all 0 replies
-
The Wall Street Transcript
Celgene Corporation ($CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane- http://su.pr/1wgenU - View all 0 replies
-
Holly Thompson
Celgene $CELG reports Q1 EPS of $1.37 beats by $0.01. Revenue of $1.46B (+15% Y/Y) misses by $0.01B. - View all 0 replies
-
- View all 4 replies
-
-
The Aristos: Biotech diving. Can't go up continuously. Will recover but where is the question.
-
Jim Van Meerten
$CELG - 100% Barchart technical buy signals - 8 new highs and up 10.24% in the last month - Relative strength Index 78.63% - View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 5 2013 | $CELG $FB $FFIV $NIHD $RDWR | SharePlanner http://bit.ly/17gVXmw - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 4 replies
-
-
The Aristos: Biotech diving. Can't go up continuously. Will recover but where is the question.
-
StockBeaver
According to my analysis, $CELG has been overbought since Jan 7th. I like the company... Analysis: http://bit.ly/YkcTGM - View all 4 replies
-
StockBeaver: I'm working on this feature of allowing users to 'Search'. Two challenges: 1. The site is currently optimized for reads. It's zippy!
-
StockBeaver: The 2nd issue is that any input field on a website is window for hackers. Currently stockbever.com has 0 input fields.
-
- View all 2 replies
-
-
-
Chimera Research Group
$CELG $CELG Abraxane ph 3 pancreatic cancer trial shows stat sig improvemnt in overall survival! Suggested this back in June for subscribrs - View all 1 replies
-
-
The Scientist
CELG Abraxane P3 panc ca studies likely to be a bust. Trial began 3/09; near end of trial 9/11, had to add 210 pts to the study - View all 2 replies
-
The Scientist: Only logical reason to add more pts was that OS data was weak; more pts were needed to raise OS data
-
-
The Scientist
Awaiting CELG Abraxane data on panc CA. SPARC hypothesis controversial. Abrax does not improve OS in breast CA, which is usually SPARC+. - View all 2 replies
-
The Scientist: Perhaps destroying SPARC/stroma promotes metastasis - allows for easier malignant cell escape. Abrax should have worked better in breast CA.
-
-
- View all 1 replies
-
-
- View all 1 replies
-
blablah: Do not understand the reason for such a big drop. Revlimid's usage is ever increasing and the withdrawal was only for certain strength
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 5 replies
-
-
Maria Auziliadora: That stock will come back though that's m feeling maybe not today!!!
-
- View all 1 replies
-
Oceanstats: I feel you pain...sold DANG yesterday after soaring.....soaring even more today! DANG IT!
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
-
- View all 4 replies
-
0ZJ: ...I'm thinking I was at least a day earlier. Per my indicators I could short again today. Comtemplating it.
-
ker.nulov@gmail.com: I mean, when current month's (high - low) value is inside previous month's (high-low) which usually means that no trend change happened.
-
- View all 1 replies
-